Volume | 157,440 |
|
|||||
News | - | ||||||
Day High | 3.25 | Low High |
|||||
Day Low | 3.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NRX Pharmaceuticals Inc | NRXP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.23 | 3.02 | 3.25 | 3.18 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,026 | 157,440 | $ 3.15 | $ 496,499 | - | 1.90 - 12.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:30:09 | 8 | $ 3.18 | USD |
NRX Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
267.7M | 83.92M | - | 0 | -30.16M | -0.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NRX Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRXP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.83 | 3.29 | 2.674 | 2.97 | 357,464 | 0.35 | 12.37% |
1 Month | 4.26 | 4.30 | 1.90 | 2.97 | 823,644 | -1.08 | -25.35% |
3 Months | 4.686 | 7.333 | 1.90 | 4.81 | 1,524,779 | -1.51 | -32.14% |
6 Months | 3.479 | 7.333 | 1.90 | 4.58 | 1,228,151 | -0.299 | -8.59% |
1 Year | 6.40 | 12.00 | 1.90 | 4.12 | 1,076,666 | -3.22 | -50.31% |
3 Years | 230.10 | 262.40 | 1.90 | 68.52 | 1,601,214 | -226.92 | -98.62% |
5 Years | 230.10 | 262.40 | 1.90 | 68.52 | 1,601,214 | -226.92 | -98.62% |
NRX Pharmaceuticals Description
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |